GAITHERSBURG, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025.
Altimmune management will host a conference call at 8:30 am E.T. on February 27 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors.
Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com
This press release was published by a CLEAR® Verified individual.
– Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of…
Oslo, 24 May 2025: Zelluna ASA (the "Company") refers to the resolution by the Company's…
Los Angeles, CA and Vancouver, BC, May 23, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc.…
$3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon…
INDIANAPOLIS, May 23, 2025 /PRNewswire/ -- This Memorial Day Weekend, the spotlight won't only be on…
IRVING, Texas, May 23, 2025 /PRNewswire/ -- Caris Life Sciences® ("Caris"), a leading, patient-centric, next-generation AI…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="1px" width="1px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
